Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review
Open accessThe DOI matches its Crossref record; 84 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet; 31 of the 64 sources its claims cite were checked for support.
Abstract
The co-occurrence of substance use disorders (SUDs) and psychiatric conditions, often referred to as comorbidity or concurrent disorders, presents intricate challenges in both diagnosis and treatment. This comprehensive narrative review aims to synthesize and critically evaluate the existing evidence surrounding the management of individuals with comorbid SUDs and psychiatric disorders. Comorbidity in these domains carries profound implications for clinical practice, research, and policymaking, emphasizing the need for a holistic understanding of the intricate dynamics that arise when these conditions coexist. This review explores recent research findings, evidence-based guidelines, and emerging trends within the field, offering valuable insights for clinicians, researchers, and policymakers seeking to navigate the complex terrain of comorbidity in substance use and psychiatric disorders. © 2024 by the author.
Verified 2026-11-19 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
This is a narrative review of how to manage co-occurring substance use disorders (SUDs) and psychiatric disorders, emphasizing that diagnosis and treatment are complicated by overlapping symptoms, self-medication, and social factors. The paper argues that integrated, individualized, and holistic care is preferred over serial care, while noting that evidence for some pharmacologic and psychotherapeutic strategies remains limited or mixed.
Key findings
- Dual diagnosis is common and clinically consequential: in a US study using National Epidemiologic Survey on Alcohol and Related Conditions Wave III data, adults with dual diagnoses accounted for 26% of those with psychiatric disorders, 37% of those with SUDs, and 18% of the total 76 million adults with either condition.
- Among children/adolescents in a systematic review, dual-diagnosis prevalence ranged from 18% to 54%, with an average prevalence of 33%; males were more likely to experience dual diagnoses, and affective disorders were the most prevalent psychiatric diagnoses.
- Integrated care is presented as the favored treatment model: studies cited in the paper found it improves treatment engagement, substance use, mental health, and overall quality of life.
- Psychosocial treatments and some medications show promise, but evidence is uneven: meta-reviews found psychosocial treatments produce small to moderate benefits versus inactive controls in the short term, and clozapine has been associated with higher odds of abstinence and reduced psychiatric hospitalization, though the paper says evidence remains inconclusive due to limited samples and incomplete reporting in randomized trials.
Methods
- This is a comprehensive narrative review synthesizing existing evidence, recent research findings, evidence-based guidelines, and emerging trends on comorbid SUDs and psychiatric disorders.
- The paper draws on prior reviews, meta-analyses, systematic reviews, guidelines, and selected studies across topics including integrated care, pharmacologic treatment, psychotherapy, harm reduction, alcohol use disorder with mood/anxiety disorders, and stimulant use disorder with ADHD.
- No new dataset, sample, or primary statistical analysis was conducted; the paper is a literature synthesis.
Limitations
- The paper states that evidence for several interventions is limited, mixed, or inconclusive, including pharmacological treatments in general, clozapine because of limited sample sizes and insufficient reporting in randomized controlled trials, and prescription stimulants for stimulant use disorder.
- It also notes that harm reduction’s impact on people with comorbid conditions remains less well-defined, and that more research is needed to assess interventions tailored to this population.
- Evident from the text: because this is a narrative review, it does not present a systematic search strategy, formal quality assessment, or pooled effect estimates (not stated in the paper).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
18 Valid · 1 Not valid · 14 Not checked · 4 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“the prevalence of dual diagnoses within this specific target population ranged from 18% to 54%, with an average prevalence of 33%.”
§ Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review > 2. Prevalence and Characteristics of Dual Diagnoses
What the sources say
- Supportedcites [9] Tomáš J. Lenka Š. Prevalence of Dual Diagnoses among Children and Adolescents with Mental Health Conditions Children 2023 10 293 10.3390/children10020293 36832422 PMC9955022 source
Section 3.1 reports that prevalence among children and adolescents treated primarily for mental health conditions ranged from 18.3% to 54%, with a mean of 32.7%. The citing sentence rounds these figures to 18%–54% and 33%. The same section cautions that study sample sizes differed and the rates are not strictly comparable. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“current evidence strongly supports an approach known as integrated care.”
§ Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review > 4. The Role of Integrated Care
What the sources say
- Not checked — no full text of the sourcecites [12] Crockford D. Current Challenges With Comorbid Psychiatric and Substance Use Disorders Can. J. Addict. 2021 12 4 10.1097/CXA.0000000000000121 source
- Partly supportedcites [14] George T.P. Welsh L. Franchuk S.L. Vaccarino F.J. Why Integrating Medications and Psychosocial Interventions Is Important to Successfully Address the Opioid Crisis in Canada Can. J. Psychiatry 2022 67 176 178 10.1177/07067437211037625 34424059 PMC8935597 sourceExperimental — accuracy not yet measured
“Putting it All Together” advocates integrated mental health, addiction, and medical care for people with opioid use disorder (OUD). But the paper addresses OUD specifically, rather than comorbid substance use disorders and psychiatric conditions generally. “The Importance of Integrating PSIs into the Treatment of OUD” also says evidence for combining psychosocial interventions with opioid agonist treatment is mixed, so “strongly supports” overstates that evidence. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“psychosocial treatments yield small to moderate benefits compared to inactive controls in the short-term [39,40,41,42,43,44].”
§ Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review > 6. Psychotherapeutic Approaches
What the sources say
- Not checked — no full text of the sourcecites [39] Dellazizzo L. Potvin S. Giguère S. Landry C. Léveillé N. Dumais A. Meta-Review on the Efficacy of Psychological Therapies for the Treatment of Substance Use Disorders Psychiatry Res. 2023 326 115318 10.1016/j.psychres.2023.115318 37356250 source
- Partly supportedcites [40] Subodh B.N. Sharma N. Shah R. Psychosocial Interventions in Patients with Dual Diagnosis Indian J. Psychiatry 2018 60 S494 S500 10.4103/psychiatry.IndianJPsychiatry_18_18 29540920 PMC5844161 sourceExperimental — accuracy not yet measured
The Introduction reports narrow benefits from adding psychosocial interventions to usual medical treatment in patients with dual diagnosis. It does not quantify those benefits as small to moderate or establish a short-term advantage over inactive controls. The section on psychotic disorders and substance use disorders instead describes the comparative evidence as insufficient. (LLM, conf=0.82)
- Partly supportedcites [41] Barbui C. Purgato M. Abdulmalik J. Acarturk C. Eaton J. Gastaldon C. Gureje O. Hanlon C. Jordans M. Lund C. Efficacy of Psychosocial Interventions for Mental Health Outcomes in Low-Income and Middle-Income Countries: An Umbrella Review Lancet Psychiatry 2020 7 162 172 10.1016/S2215-0366(19)30511-5 31948935 sourceExperimental — accuracy not yet measured
The Description of included systematic reviews (page unavailable) reports comparisons of psychosocial interventions with inactive controls, but its list of studied populations does not include substance use disorders. The Discussion (page unavailable) reports benefits for several other mental health conditions and says long-term effectiveness was seldom assessed. It does not establish small-to-moderate short-term benefits for SUDs. (LLM, conf=0.83)
- Partly supportedcites [42] Volkow N.D. Personalizing the Treatment of Substance Use Disorders Am. J. Psychiatry 2020 177 113 116 10.1176/appi.ajp.2019.19121284 32008390 sourceExperimental — accuracy not yet measured
In “Treating the Dimensions of Substance Use Disorder” (page not specified), the paper says cognitive-behavioral treatments and contingency management have benefits for specific aspects of addiction. It does not quantify those benefits as small to moderate or compare them with inactive controls over the short term. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [43] Lappan S.N. Brown A.W. Hendricks P.S. Dropout Rates of In-Person Psychosocial Substance Use Disorder Treatments: A Systematic Review and Meta-Analysis Addiction 2020 115 201 217 10.1111/add.14793 31454123 source
- Not checked — no full text of the sourcecites [44] Gaznick N. Judd P.A. Psychosocial Treatment of Substance Use Disorders Absolute Addiction Psychiatry Review: An Essential Board Exam Study Guide Marienfeld C. Springer International Publishing Cham, Switzerland 2020 71 85 978-3-030-33404-8 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Left untreated, MDD among individuals with AUD can have profound consequences [65].”
§ Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review > 8. Addressing Comorbidity in Alcohol Use Disorders and Anxiety/Depression
What the sources say
- Partly supportedcites [65] Samet S. Fenton M.C. Nunes E. Greenstein E. Aharonovich E. Hasin D. Effects of Independent and Substance-Induced Major Depressive Disorder on Remission and Relapse of Alcohol, Cocaine and Heroin Dependence Addiction 2013 108 115 123 10.1111/j.1360-0443.2012.04010.x 22775406 PMC3767419 sourceExperimental — accuracy not yet measured
The Discussion reports that MDD increased relapse risk among patients with alcohol dependence, supporting the claim that it can have serious consequences. But the study did not establish those consequences specifically for untreated MDD: it controlled for treatment and did not analyze depression-treatment status in detail. No page numbers are available in our copy. (LLM, conf=0.86)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence-based strategies, including contingency management (CM), cognitive-behavioral therapy (CBT), dialectical behavior therapy (DBT), motivational interviewing (MI), acceptance and commitment therapy (ACT), and family-based interventions, have demonstrated their effectiveness in reducing substance use and enhancing treatment outcomes”
§ Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review > 6. Psychotherapeutic Approaches
What the sources say
- Not checked — no full text of the sourcecites [45] Krausz M. Vogel M. Ploesser M. Care for Patients with Addiction and Concurrent Disorders in Europe, The United States of America, and Canada: Similarities and Differences Co-Occurring Addictive and Psychiatric Disorders: A Practice-Based Handbook from a European Perspective Dom G. Moggi F. Springer Berlin/Heidelberg, Germany 2015 47 59 978-3-642-45375-5 source
- Not checked — no full text of the sourcecites [46] Lee N.K. Cameron J. Jenner L. A Systematic Review of Interventions for Co-Occurring Substance Use and Borderline Personality Disorders Drug Alcohol Rev. 2015 34 663 672 10.1111/dar.12267 25919396 source
- Partly supportedcites [47] Harada T. Tsutomi H. Mori R. Wilson D.B. Cognitive-behavioural Treatment for Amphetamine-type Stimulants (ATS)-use Disorders Cochrane Database Syst. Rev. 2018 10.1002/14651858.CD011315.pub2 PMC6516990 30577083 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [48] Ronsley C. Nolan S. Knight R. Hayashi K. Klimas J. Walley A. Wood E. Fairbairn N. Treatment of Stimulant Use Disorder: A Systematic Review of Reviews PLoS ONE 2020 15 e0234809 10.1371/journal.pone.0234809 32555667 PMC7302911 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [49] Magill M. Ray L. Kiluk B. Hoadley A. Bernstein M. Tonigan J.S. Carroll K. A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition J. Consult. Clin. Psychol. 2019 87 1093 1105 10.1037/ccp0000447 31599606 PMC6856400 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [50] Ray L.A. Meredith L.R. Kiluk B.D. Walthers J. Carroll K.M. Magill M. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-Analysis JAMA Netw. Open 2020 3 e208279 10.1001/jamanetworkopen.2020.8279 32558914 PMC7305524 sourceExperimental — accuracy not yet measured
The Introduction calls CBT a first-line treatment for alcohol and other substance use disorders, and the Results report reduced substance-use frequency and quantity for CBT plus pharmacotherapy versus usual care plus pharmacotherapy. The Discussion also describes contingency management and other behavioral treatments as having empirical support. The paper does not establish effectiveness for the full list in the claim: the passages found do not assess dialectical behavior therapy, acceptance and commitment therapy, or family-based interventions. (LLM, conf=0.88)
- Not matchedcites [51] Haktanir A. Callender K. Meta-Analysis of Dialectical Behavior Therapy (DBT) for Treating Substance Use Res. Educ. Psychol. 2020 4 74 87
We searched by its title and found no matching paper.
- Partly supportedcites [52] Hakobyan S. Vazirian S. Lee-Cheong S. Krausz M. Honer W.G. Schutz C.G. Concurrent Disorder Management Guidelines. Systematic Review J. Clin. Med. 2020 9 2406 10.3390/jcm9082406 32731398 PMC7463987 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that integrated care for people with concurrent disorders reduced substance use and improved mental health compared with standard care. It does not establish those outcomes for the six named strategies individually; searches for their names found no such findings in our copy. (LLM, conf=0.84)
- Partly supportedcites [53] López G. Orchowski L.M. Reddy M.K. Nargiso J. Johnson J.E. A Review of Research-Supported Group Treatments for Drug Use Disorders Subst. Abuse Treat. Prev. Policy 2021 16 51 10.1186/s13011-021-00371-0 34154619 PMC8215831 sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) report reduced substance use or improved outcomes for CBT, CM, and brief motivational interviewing in specific drug-use settings. The review also reports benefit from DBT for people with co-occurring substance use disorder and borderline personality disorder. The Method section describes family therapy but does not establish its effectiveness, and no passage found addresses acceptance and commitment therapy; the claim therefore overstates what this review supports. (LLM, conf=0.88)
- Partly supportedcites [54] Magill M. Kiluk B.D. Ray L.A. Efficacy of Cognitive Behavioral Therapy for Alcohol and Other Drug Use Disorders: Is a One-Size-Fits-All Approach Appropriate? Subst. Abuse Rehabil. 2023 14 1 11 10.2147/SAR.S362864 36844999 PMC9948631 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) reports that CBT is generally more effective than usual community care and that CBT combined with motivational interviewing or contingency management is efficacious. The Introduction names dialectical behavior therapy and acceptance and commitment therapy as related approaches, but does not establish their effectiveness for substance use; the paper also does not establish effectiveness for family-based interventions. The claim therefore extends beyond the evidence this source reports. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims · 9 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 10
Citations
Cites
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Implementing Dual Diagnosis Services for Clients With Severe Mental Illness
Drake, R. E., Essock, S. M., Shaner, A., Carey, K. B., Minkoff, K., Kola, L., Lynde, D., Osher, F. C., Clark, R. E., & Rickards, L. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.4.469 · Cited by 693
Cognitive Behavioral Therapy for Substance Use Disorders
McHugh, R. K., Hearon, B. A., & Otto, M. W. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.012 · Cited by 626 · cited 1×
“…(DBT), motivational interviewing (MI), acceptance and commitment therapy (ACT), and family-based interventions, have demonstrated their effectiveness in reducing substance use and enhancing treatment outcomes by addressing the psychological, behavioral, and social aspects of addiction [45–56].”
BackgroundCo-Occurring Mental and Substance Use Disorders: The Neurobiological Effects of Chronic Stress
Brady, K. T., & Sinha, R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1483 · Cited by 552
Treatment engagement of individuals experiencing mental illness: review and update
Dixon, L. B., Holoshitz, Y., & Nossel, I. (2016) · World Psychiatry · doi:10.1002/wps.20306 · Cited by 550 · cited 1×
“By leveraging the potential benefits of pharmacological interventions within a broader treatment framework, we can optimize outcomes for individuals with dual diagnoses [32,33].”
BackgroundAlcoholics Anonymous and other 12-step programs for alcohol use disorder
Kelly, J. F., Humphreys, K., & Ferri, M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012880.pub2 · Cited by 462 · cited 1×
“The effectiveness of 12-step group facilitation interventions, such as Alcoholics Anonymous (AA), in addressing SUDs, particularly alcohol use disorder (AUD), is supported by high-quality evidence [57], showing their efficacy in promoting abstinence.”
BackgroundDrake, R. E., Mueser, K. T., Brunette, M. F., & McHugo, G. J. (2004) · Psychiatric Rehabilitation Journal · doi:10.2975/27.2004.360.374 · Cited by 459
Motivational interviewing for substance abuse
Smedslund, G., Berg, R. C., Hammerstrøm, K. T., Steiro, A., Leiknes, K. A., Dahl, H. M., & Karlsen, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008063.pub2 · Cited by 408
Integrated treatment of substance use and psychiatric disorders
Kelly, T. M., & Daley, D. C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.774673 · Cited by 378 · cited 1×
“It encompasses a diverse array of approaches, including pharmacological, psychotherapeutic, and integrated strategies, with the overarching aim of providing profound insights and guidance to those at the forefront of addiction and psychiatry [4].”
BackgroundLappan, S. N., Brown, A. W., & Hendricks, P. S. (2020) · Addiction · doi:10.1111/add.14793 · Cited by 370
Barbui, C., Purgato, M., Abdulmalik, J., Acarturk, C., Eaton, J., Gastaldon, C., Gureje, O., Hanlon, C., Jordans, M., Lund, C., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30511-5 · Cited by 349
Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000193 · Cited by 333 · cited 1×
“Psychosocial interventions have demonstrated significant promise in the treatment of individuals with comorbid substance use and psychiatric disorders [37,38].”
BackgroundStein, D. J., Shoptaw, S. J., Vigo, D. V., Lund, C., Cuijpers, P., Bantjes, J., Sartorius, N., & Maj, M. (2022) · World Psychiatry · doi:10.1002/wps.20998 · Cited by 331 · cited 1×
“By leveraging the potential benefits of pharmacological interventions within a broader treatment framework, we can optimize outcomes for individuals with dual diagnoses [32,33].”
BackgroundMagill, M., Ray, L., Kiluk, B., Hoadley, A., Bernstein, M., Tonigan, J. S., & Carroll, K. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000447 · Cited by 315
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284 · cited 1×
“Integrated care recognizes that these external factors play a pivotal role in an individual’s overall well-being and treatment outcome [16].”
BackgroundRay, L. A., Meredith, L. R., Kiluk, B. D., Walthers, J., Carroll, K. M., & Magill, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8279 · Cited by 265
Bahji, A., Mazhar, M. N., Hudson, C. C., Nadkarni, P., MacNeil, B. A., & Hawken, E. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.01.007 · Cited by 241 · cited 1×
“For instance, approximately one in five individuals with an eating disorder will develop an SUD at some point in their lifetime, with one in ten currently meeting SUD criteria [5].”
BackgroundSelf-citationTreatment of stimulant use disorder: A systematic review of reviews
Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., Wood, E., & Fairbairn, N. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234809 · Cited by 222 · cited 1×
“An example of this shortfall is the inadequacy of high-quality research regarding the effectiveness of CBT in the treatment of stimulant use disorders [47,48,58].”
BackgroundZulauf, C. A., Sprich, S. E., Safren, S. A., & Wilens, T. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-013-0436-6 · Cited by 214 · cited 1×
“In essence, addressing the comorbidity of stimulant use disorders and ADHD calls for a nuanced approach that carefully considers the intricate interplay of various factors and acknowledges the existing gaps in evidence [75].”
BackgroundPharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194 · cited 1×
“However, unlike the decades of evidence supporting various forms of opioid agonist therapy for treating opioid use disorder, the current body of evidence supporting prescription stimulants for treating stimulant use disorders remains inconclusive [58,66–69].”
BackgroundPersonalizing the Treatment of Substance Use Disorders
Volkow, N. D. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19121284 · Cited by 172
Evidence Based Psychosocial Interventions in Substance Use
Jhanjee, S. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.130960 · Cited by 154
Treatment Strategies for Co-Occurring ADHD and Substance Use Disorders
Mariani, J. J., & Levin, F. R. (2007) · The American Journal on Addictions · doi:10.1080/10550490601082783 · Cited by 153
Rethinking the paradigms that inform behavioral treatment research for substance use disorders
Morgenstern, J., & McKay, J. R. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01882.x · Cited by 137
Antidepressants for the treatment of people with co-occurring depression and alcohol dependence
Agabio, R., Trogu, E., & Pani, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008581.pub2 · Cited by 131 · cited 1×
“Moreover, Cochrane reviews have highlighted the potential utility of SSRIs in treating MDD, anxiety disorders, AUD, or combinations of these conditions in individuals with co-occurring AUD, with minimal risk of adverse effects [63,64].”
BackgroundAlcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System
Bahorik, A. L., Satre, D. D., Kline-Simon, A. H., Weisner, C. M., & Campbell, C. I. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000260 · Cited by 126 · cited 1×
“Studies have shown that individuals receiving integrated care experience enhanced treatment engagement, reduced substance use, improved mental health, and an overall better quality of life [20,21].”
BackgroundTorrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.663296 · Cited by 122 · cited 1×
“Comorbidity in these domains carries substantial implications for clinical practice, research, and policymaking [2,3].”
BackgroundTreatment of Dual Diagnosis Disorders
Murthy, P., & Chand, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328351a3e0 · Cited by 115 · cited 1×
“Integrated care models, which combine SUD and mental health treatment, have demonstrated efficacy in improving outcomes for this complex population [18].”
BackgroundNon-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder
Pliszka, S. R. (2003) · CNS Spectrums · doi:10.1017/s1092852900018460 · Cited by 111
Psychostimulant drugs for cocaine dependence
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub4 · Cited by 110 · cited 2×
“However, unlike the decades of evidence supporting various forms of opioid agonist therapy for treating opioid use disorder, the current body of evidence supporting prescription stimulants for treating stimulant use disorders remains inconclusive [58,66–69].”
BackgroundConcurrent Disorder Management Guidelines. Systematic Review
Hakobyan, S., Vazirian, S., Lee-Cheong, S., Krausz, M., Honer, W. G., & Schutz, C. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082406 · Cited by 99
Samet, S., Fenton, M. C., Nunes, E., Greenstein, E., Aharonovich, E., & Hasin, D. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04010.x · Cited by 98 · cited 1×
“Left untreated, MDD among individuals with AUD can have profound consequences [65].”
BackgroundPharmacotherapy for anxiety and comorbid alcohol use disorders
Ipser, J. C., Wilson, D., Akindipe, T. O., Sager, C., & Stein, D. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007505.pub2 · Cited by 93 · cited 1×
“Moreover, Cochrane reviews have highlighted the potential utility of SSRIs in treating MDD, anxiety disorders, AUD, or combinations of these conditions in individuals with co-occurring AUD, with minimal risk of adverse effects [63,64].”
BackgroundKrause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86 · cited 1×
“…of such treatments remains inconclusive due to limited sample sizes and insufficient reporting in randomized controlled trials, emphasizing the importance of integrating medication into a comprehensive treatment approach that includes psychotherapeutic interventions and social support [29–31].”
BackgroundCognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders
Harada, T., Tsutomi, H., Mori, R., & Wilson, D. B. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011315.pub2 · Cited by 76 · cited 1×
“An example of this shortfall is the inadequacy of high-quality research regarding the effectiveness of CBT in the treatment of stimulant use disorders [47,48,58].”
BackgroundLee, N. K., Cameron, J., & Jenner, L. (2015) · Drug and Alcohol Review · doi:10.1111/dar.12267 · Cited by 74 · cited 1×
“…review by Lee et al. aimed to identify effective treatment options for individuals with comorbid substance use and borderline personality disorders, with findings suggesting that both DBT and dynamic deconstructive psychotherapy (DDP) exhibited some beneficial effects in symptom reduction [46].”
BackgroundCanadian Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder
Wood, E., Bright, J., Hsu, K., Goel, N., Ross, J. W. G., Hanson, A., Teed, R., Poulin, G., Denning, B., Corace, K., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230715 · Cited by 74 · cited 1×
“This complexity is further underscored by the recent Canadian guideline on high-risk drinking and AUD management, which raises concerns regarding the use of SSRIs in individuals with AUD and non-substance-induced Major Depressive Disorder (MDD) or anxiety disorders [59].”
BackgroundTreatment of Co-occurring Anxiety Disorders and Substance Use Disorders
McHugh, R. K. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000058 · Cited by 71
Substance Use Disorders and Anxiety: A Treatment Challenge for Social Workers
Brady, K. T., Haynes, L. F., Hartwell, K. J., & Killeen, T. K. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.774675 · Cited by 68 · cited 1×
“While some individuals may benefit from medications targeting substance cravings or withdrawal symptoms, others may require psychiatric medications to manage mood and anxiety disorders [24–27].”
BackgroundKikkert, M., Goudriaan, A., de Waal, M., Peen, J., & Dekker, J. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.09.005 · Cited by 67 · cited 1×
“Studies have shown that individuals receiving integrated care experience enhanced treatment engagement, reduced substance use, improved mental health, and an overall better quality of life [20,21].”
BackgroundTreatment for Substance Use Disorder with Co-Occurring Mental Illness
Iqbal, M. N., Levin, C. J., & Levin, F. R. (2019) · Focus · doi:10.1176/appi.focus.20180042 · Cited by 66 · cited 1×
“Pharmacological interventions play a pivotal role in the treatment of SUDs and psychiatric conditions [22].”
BackgroundIntegrating Treatment for Co-Occurring Mental Health Conditions
Yule, A. (2019) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v40.1.07 · Cited by 63 · cited 1×
“Medications designed to address both substance misuse and mental health symptoms can be integral components of individualized treatment plans [23].”
BackgroundChan, B., Freeman, M., Ayers, C., Korthuis, P. T., Paynter, R., Kondo, K., & Kansagara, D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108193 · Cited by 56
Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders
Dellazizzo, L., Potvin, S., Giguère, S., Landry, C., Léveillé, N., & Dumais, A. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115318 · Cited by 55 · cited 1×
“…evaluating the efficacy of psychotherapies for SUDs, spanning a range of substances such as alcohol, cannabis, stimulants, opioids, and benzodiazepines, have consistently shown that psychosocial treatments yield small to moderate benefits compared to inactive controls in the short-term [39–44].”
BackgroundPharmacotherapy of Comorbid Mood, Anxiety, and Substance Use Disorders
Brady, K. T., & Verduin, M. L. (2005) · Substance Use & Misuse · doi:10.1080/10826080500294924 · Cited by 52
Magill, M., Kiluk, B. D., & Ray, L. A. (2023) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s362864 · Cited by 50
A Review of Research-Supported Group Treatments for Drug Use Disorders
López, G., Orchowski, L. M., Reddy, M. K., Nargiso, J., & Johnson, J. E. (2021) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/s13011-021-00371-0 · Cited by 48
Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician
Barbuti, M., Maiello, M., Spera, V., Pallucchini, A., Brancati, G., Maremmani, A., Perugi, G., & Maremmani, I. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093096 · Cited by 47
Radonjić, N. V., Bellato, A., Khoury, N. M., Cortese, S., & Faraone, S. V. (2023) · CNS Drugs · doi:10.1007/s40263-023-01005-8 · Cited by 45
Tran, M. T. N., Luong, Q. H., Le Minh, G., Dunne, M. P., & Baker, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.512076 · Cited by 42 · cited 1×
“Psychosocial interventions have demonstrated significant promise in the treatment of individuals with comorbid substance use and psychiatric disorders [37,38].”
BackgroundThe Challenge of Dual Diagnosis.
WOODY, G. E. (1996) · PubMed Central · Cited by 41
Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221142575 · Cited by 41
Self-citationAlcohol and Alcohol-related Diseases
(2023) · doi:10.1007/978-3-031-32483-3 · Cited by 38
Jegede, O., Rhee, T. G., Stefanovics, E. A., Zhou, B., & Rosenheck, R. A. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114720 · Cited by 34 · cited 1×
“In a recent US study [8], using data from the National Epidemiologic Survey on Alcohol and Related Conditions Wave III, researchers compared adults with dual diagnoses to those with either psychiatric disorders or substance use disorders (SUDs).”
MethodContinuity of Care in Dual Diagnosis Treatment: Definitions, Applications, and Implications
McCallum, S., Mikocka‐Walus, A. A., Turnbull, D. A., & Andrews, J. M. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1104930 · Cited by 33 · cited 1×
“The careful selection and monitoring of medications, along with ongoing evaluation of their effectiveness, are crucial aspects of treatment [28].”
BackgroundGrant, S., Azhar, G., Han, E., Booth, M., Motala, A., Larkin, J., & Hempel, S. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003822 · Cited by 31 · cited 1×
“In fact, some research suggests that combining SSRIs with AUD treatment can yield significant benefits, emphasizing the critical importance of addressing both conditions concurrently [60–62].”
BackgroundDual Diagnosis and Application Problems in the Use of the Construct: A Review of Literature
Iudici, A., Girolimetto, R., Volponi, G., & Eletto, A. (2020) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000001092 · Cited by 25 · cited 1×
“…explored some of the clinical intricacies of dual diagnosis, where SUDs coincide with psychological or psychiatric disorders, revealing significant issues across various thematic areas and emphasizing the need for innovative approaches and alternative theoretical frameworks in future research [13].”
BackgroundTheis (2016) · doi:10.1016/j.cnur.2016.01.007 · Cited by 24
Psychosocial Interventions in Patients with Dual Diagnosis
Subodh, B., Sharma, N., & Shah, R. (2018) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_18_18 · Cited by 22
Meta-Analysis of Dialectical Behavior Therapy (DBT) for Treating Substance Use
Haktanır, A., & Callender, K. A. (2020) · DergiPark (Istanbul University) · Cited by 20
Pharmacological treatment for dual diagnosis: a literature update and a proposal of intervention
Vitali, M., Mistretta, M., Alessandrini, G., Coriale, G., Romeo, M., Attilia, F., Rotondo, C., Sorbo, F., Pisciotta, F., Attilia, M. L., et al. (2018) · Rivista di Psichiatria · doi:10.1708/2925.29419 · Cited by 19 · cited 1×
“Medication alone seldom serves as a comprehensive solution for addressing comorbidity, underscoring the importance of integrating it into a broader treatment framework that encompasses psychotherapeutic interventions and social support [34–36].”
BackgroundPrevalence of Dual Diagnoses among Children and Adolescents with Mental Health Conditions
Tomáš, J., & Lenka, Š. (2023) · Children · doi:10.3390/children10020293 · Cited by 18
Skryabin, V. Y., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., & Bulatova, R. A. (2021) · Journal of Addictive Diseases · doi:10.1080/10550887.2021.1905589 · Cited by 17 · cited 1×
“…of such treatments remains inconclusive due to limited sample sizes and insufficient reporting in randomized controlled trials, emphasizing the importance of integrating medication into a comprehensive treatment approach that includes psychotherapeutic interventions and social support [29–31].”
BackgroundGeorge, T. P., Welsh, L., Franchuk, S. L., & Vaccarino, F. J. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211037625 · Cited by 14 · cited 1×
“Effectively addressing comorbid SUDs and psychiatric conditions demands a comprehensive treatment approach [12,14].”
BackgroundStorebø, O. J., & Gluud, C. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2019-111328 · Cited by 13 · cited 1×
“As a result, clinicians often approach the prescription of psychostimulants with caution, concerned about the potential for worsening substance use outcomes and the risk of mis-use [69,71].”
BackgroundTang, V. M., Yu, D., Weissman, C. R., Jones, B. D. M., Wang, G., Sloan, M. E., Blumberger, D. M., Daskalakis, Z. J., Le Foll, B., & Voineskos, D. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.049 · Cited by 11
Substance Misuse and Young People: Critical Issues
(2019) · doi:10.4324/9780429284304 · Cited by 10
Concurrent Disorders Management in Psychiatric Care: Opportunities and Challenges
Danilewitz, M., Bahji, A., Lamba, W., Chopra, N., & George, T. P. (2021) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000122 · Cited by 10 · cited 1×
“Medication alone seldom serves as a comprehensive solution for addressing comorbidity, underscoring the importance of integrating it into a broader treatment framework that encompasses psychotherapeutic interventions and social support [34–36].”
BackgroundSelf-citationDanilewitz, M., & Bahji, A. (2021) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000128 · Cited by 10 · cited 1×
“Likewise, evidence suggests a disproportionate impact of opioid use disorder (OUD) among individuals with schizophrenia, who are less likely to receive opioid agonist therapy (OAT) and tend to have a poorer prognosis [6].”
BackgroundSelf-citationAlcoholics Anonymous and other 12-step programs for alcohol use disorder
Kelly, J. F., Humphreys, K. N., & Ferri, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012880 · Cited by 10
Larsen, J. L., Johansen, K. S., & Mehlsen, M. Y. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.825701 · Cited by 9 · cited 2×
“The co-occurrence of SUDs and psychiatric conditions is characterized by the intricate interplay between the psychological, biological, and social underpinnings of these dual conditions [10].”
BackgroundNavigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders
Bahji, A., Danilewitz, M., & Crockford, D. (2023) · Brain Sciences · doi:10.3390/brainsci13101416 · Cited by 9
Self-citationCombined Medication with Stimulants and Non-Stimulants for Attention-Deficit/Hyperactivity Disorder
Bahn, G. H., & Seo, K. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.4.705 · Cited by 8 · cited 1×
“In such cases, non-stimulant medications like atomoxetine are frequently preferred despite the potential advantages offered by long-acting prescription stimulants [72,73].”
BackgroundBahji, A., Danilewitz, M., Vazquez, G., & Patten, S. (2021) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000123 · Cited by 6 · cited 1×
“Additionally, comorbidity with cannabis use disorder (CUD) is notably higher among individuals with bipolar disorder [7].”
BackgroundManaging Adult Attention-Deficit/Hyperactivity Disorder With Comorbid Substance Use Disorder
Ward, B., Bahji, A., & Crockford, D. (2022) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000160 · Cited by 3 · cited 1×
“This is because the symptoms of stimulant intoxication and withdrawal can closely mimic those of ADHD [70].”
BackgroundSelf-citationFauve, C. E. L. (2004) · Evidence-Based Mental Health · doi:10.1136/ebmh.7.4.108 · Cited by 2
Current Challenges With Comorbid Psychiatric and Substance Use Disorders
Crockford, D. (2021) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000121 · Cited by 1 · cited 2×
“Effectively addressing comorbid SUDs and psychiatric conditions demands a comprehensive treatment approach [12,14].”
BackgroundDhaliwal, A. K., Bahji, A., & Danilewitz, M. (2022) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000164 · Cited by 1
Self-citationFacing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health
(2016) · PubMed · Cited by 1
Untitled work
(2022) · doi:10.1891/ehpp-2021-0007
Cited by
Deep, P. D., Ghosh, N., Gaither, C., & Rahaman, M. S. (2024) · Psychoactives · doi:10.3390/psychoactives3040028 · Cited by 35
“Bahji notes that the intricate interplay between the psychological, biological, and social underpinnings of these dual conditions characterizes the co-occurrence of SUDs and psychiatric conditions [34].”
InfluentialChiappini, S., Gramuglia, P. D., Mosca, A., Cavallotto, C., Miuli, A., Corkery, J., Guirguis, A., Schifano, F., & Martinotti, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1508732 · Cited by 30
Cavallotto, C., Chiappini, S., Mosca, A., d’Andrea, G., Carlo, F. D., Piro, T., Susini, O., Stefanelli, G., Cesare, A. D., Ricci, V., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082206 · Cited by 23
“Several reviews and meta-analyses consistently indicate a significantly higher prevalence of comorbidity in comparison to the general population [5].”
BackgroundMüller, V., Mellor, D., & Pikó, B. F. (2024) · Learning Disabilities Research & Practice · doi:10.1177/09388982241271511 · Cited by 13
“It is important to acknowledge that self-reported ADHD symptoms can overlap with other conditions, including substance use disorders (Bahji, 2024), autism spectrum disorder (Waldren et al., 2024), learning disabilities (Kellens et al., 2024), bipolar disorder (Barden et al., 2023), mood disorders…”
Concurrent Disorders and Treatment Outcomes: A Meta-Analysis
Scott, K. D., & Gorey, K. M. (2025) · Journal of Dual Diagnosis · doi:10.1080/15504263.2025.2515015 · Cited by 18
“The need for treatment integration seems clear, yet institutions seem to remain staunchly siloed, keeping addiction treatment separate from other mental health treatments (Bahji, 2024; Hakobyan et al., 2020; Wiktorowicz et al., 2019).”
Metadata
- Authors
- Bahji, A.
- Affiliations
- University of Calgary (CA)
- Corresponding author
- Bahji, Anees
- ORCID
- Bahji, Anees
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-02-09
- Volume
- 13
- Issue
- 4
- Pages
- 999
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10889170
- OpenAlex
- W4391692641
- Semantic Scholar
- 467002ddef1d8c68e4493bbe190bc32d2b192f36
- Cited by
- 83
- References
- 89
- Citations by year
- 2026: 48 · 2025: 26 · 2024: 9
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R25DA037756)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Keywords
- substance use disorders, mental illness, comorbidities, concurrent disorders, diagnosis, treatment, evidence-based recommendations, clinical practice, mental health policy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.